KamalKMubarakMD
Pulmonology • Ann Arbor, MICritical Care Medicine, Pleural Disease, Pulmonary Vascular Medicine, Restrictive Lung Disease
Physician
Dr. Mubarak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1900 Tapadera Drive
Ann Arbor, MI 48103Phone+1 734-904-9491Fax+1 734-802-2965
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 2000
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1995
Ohio State University HospitalResidency, Surgery, 1990 - 1993
Aga Khan Medical CollegeClass of 1989
Certifications & Licensure
MI State Medical License 2000 - 2027
TN State Medical License 2023 - 2026
MD State Medical License 2023 - 2025
NJ State Medical License 2024 - 2025
KY State Medical License 2023 - 2024
LA State Medical License 2022 - 2024
OK State Medical License 2022 - 2023- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2011-2013
Publications & Presentations
PubMed
- 35 citationsPrevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survivalAdriano R. Tonelli, Sebastian Fernandez-Bussy, Saba Lodhi, Olufemi Akindipe, Robin D. Carrie
The Journal of Heart and Lung Transplantation. 2010-08-01 - 1047 citationsCyclophosphamide versus placebo in scleroderma lung disease.Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan G. Goldin, Michael D. Roth
The New England Journal of Medicine. 2006-06-22 - 295 citationsEffects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Michael D. Roth, Daniel E. Furst
American Journal of Respiratory and Critical Care Medicine. 2007-11-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
